ArticleThe American journal of tropical medicine and hygiene2025
The Clinical and Epidemiologic Factors Associated with Mortality in Tuberculous Meningitis in Ceará State, Brazil.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to characterize and evaluate the risk factors for mortality in hospitalized patients with tuberculous meningitis (TBM). This was a retrospective study of hospitalized patients with TBM between 2016 and 2023 in Ceará State, Brazil. Generalized linear regression was performed to identify factors predictive of in-hospital mortality. The British Medical Research Council Severity (BMRCS) grading system for TBM was evaluated upon patient admission. Of the 94 patients with TBM enrolled in the study, the median age was 39.6 years, 86.7% were men, 81.2% were positive for HIV upon admission, 33.0% had prior tuberculosis, and 4.3% had multidrug-resistant infections. In-hospital mortality was 31.9% for all patients with a final diagnosis of TBM. When multivariable analysis was applied, significant associations with increased in-hospital mortality were seen among patients with BMRCS grade III (odds ratio [OR] 1.42; 95% CI 0.49-4.08), low hemoglobin levels (OR 6.44; 95% CI 0.59-70.27), low hematocrit levels (OR 0.53; 95% CI 0.04-5.97), higher aspartate aminotransferase (AST) levels (OR 1.98; 95% CI 0.67-5.77), and fewer cerebrospinal fluid (CSF) lymphocytes (OR 1.38; 95% CI 0.50-3.80) and decreased in-hospital mortality in those with orally administered rifampin, isoniazid, pyrazinamide, and ethambutol (RHZE) (OR 0.28; 95% CI 0.10-0.79). Mortality was higher among patients with BMRCS grade III, low hemoglobin levels, low hematocrit levels, higher AST, and fewer CSF lymphocytes, and lower in those orally administered RHZE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.